Lifitegrast, the active ingredient in Xiidra, is designed to specifically block the interaction of ICAM-1 and LFA-1, which is a key mediator of the inflammation behind Dry Eye Disease.1-3
In vitro studies have shown that Xiidra may inhibit the recruitment of previously activated T cells, the activation of newly recruited T cells, and the release of pro-inflammatory cytokines—interrupting the perpetual cycle of inflammation.1,4
The exact mechanism of action of Xiidra in Dry Eye Disease is not known.1
Important Safety Information
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.